Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-09
2011-08-09
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S159000
Reexamination Certificate
active
07994194
ABSTRACT:
This invention relates to novel compounds that are 4-oxoquinoline derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 4-oxoquinoline derivatives that are derivatives of elvitegravir. This invention also provides pyrogen-free compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an HIV integrase inhibitor, such as elvitegravir.
REFERENCES:
patent: 6221335 (2001-04-01), Foster
patent: 6440710 (2002-08-01), Keinan et al.
patent: 6603008 (2003-08-01), Ando et al.
patent: 7176220 (2007-02-01), Satoh et al.
patent: 7517990 (2009-04-01), Ito et al.
patent: 2006/0058286 (2006-03-01), Krystal et al.
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0197695 (2007-08-01), Potyen et al.
patent: 2008/0103122 (2008-05-01), Veltri
patent: WO 95/26325 (1995-10-01), None
patent: WO 2004/046115 (2004-06-01), None
patent: WO 2005/112930 (2005-12-01), None
patent: WO 2005/113509 (2005-12-01), None
patent: 2006/034001 (2006-03-01), None
patent: WO 2007/089030 (2007-08-01), None
patent: WO 2007/118651 (2007-10-01), None
patent: WO 2009/035662 (2009-03-01), None
Ekhato, J Labelled Compounds and Radiopharmaceuticals, vol. 48, pp. 179-193, 2005.
Weiss, Mag Res in Med, vol. 51, pp. 649-654, 2004.
Fisher, M.B. et al., “The Complexities Inherent in Attempts to Decrease Drug Clearance by Blocking Sites of CYP-Mediated Metabolism,”Curr. Opin. Drug Discov., 9(1): 101-109 (Jan. 2006).
Kushner, D.J. et al., “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,”Can. J. Physiol. Pharmacol., 77(2): 79-88 (Feb. 1999).
Sato, M et al., “Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics,”Journal of Medicinal Chemistry, 49(5): 1506-1508 (Mar. 5, 2006), XP002507281.
Dec. 30, 2008, International Search Report, PCT/US2008/010662.
Dec. 30, 2008, Written Opinion of the International Searching Authority, PCT/US2008/010662.
Baillie, T. A., “The Use of Stable Isotopes in Pharmacological Research,”Pharmacological Reviews, 33(2): 81-132 (1981).
Browne, T. R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,”J. Clin. Pharmacol., 38: 213-220 (1998).
Cherrah, Y., et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,”Biomedical and Environmental Mass Spectrometry, 14: 653-657 (1987).
Dyck, L. E., et al., “Effects of Deuterium Substitution on the Catabolism of β-Phenylethylamine: An In Vivo Study,”Journal of Neurochemistry, 46(2): 399-404 (1986).
Foster, A. B., “Deuterium Isotope Effects in Studies of Drug Metabolism,”Trends in Pharmacological Sciences, 5: 524-527 (1984).
Foster, A. B., “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,”Advances in Drug Research, 14: 1-40 (1985).
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,”Biomedical and Environmental Mass Spectrometry, 15: 243-247 (1988).
Haskins, N. J., “The Application of Stable Isotopes in Biomedical Research,”Biomedical Mass Spectrometry, 9(7): 269-277 (1982).
Honma S., et al., “The Metabolism of Roxatidine Acetate Hydrochloride,”Drug Metabolism and Disposition, 15(4): 551-559 (1987).
Pieniaszek, H. J., et al., “Moricizine Bioavailability via Simultaneous, Dual, Stable Isotope Administration: Bioequivalence Implications,”J. Clin. Pharmacol, 39: 817-825 (1999).
Tonn G. R., et al., “Simultaneous Analysis of Diphenhydramine and a Stable Isotope Analog (2H10) Diphenhydramine Using Capillary Gas Chromatography with Mass Selective Detection in Biological Fluids from Chronically Instrumented Pregnant Ewes,”Biological Mass Spectrometry, 22: 633-642 (1993).
Wolen, R. L., “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,”J. Clin. Pharmacol., 26: 419-424 (1986).
Notification Concerning Transmittal of International Preliminary Report on Patentability, Application No. PCT/US2008/010662, date of mailing Mar. 25, 2010.
Concert Pharmaceuticals Inc.
Hamilton Brook Smith & Reynolds P.C.
Seaman D. Margaret
LandOfFree
4-oxoquinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-oxoquinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxoquinoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2784351